Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.50 USD
Change Today -0.10 / -16.67%
Volume 6.1K
ENUM On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

enumeral biomedical holdings (ENUM) Snapshot

Open
$0.45
Previous Close
$0.60
Day High
$0.50
Day Low
$0.45
52 Week High
08/5/14 - $2.25
52 Week Low
05/21/15 - $0.30
Market Cap
25.8M
Average Volume 10 Days
44.1K
EPS TTM
$-0.12
Shares Outstanding
51.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENUMERAL BIOMEDICAL HOLDINGS (ENUM)

Related News

No related news articles were found.

enumeral biomedical holdings (ENUM) Related Businessweek News

No Related Businessweek News Found

enumeral biomedical holdings (ENUM) Details

Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp.; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

enumeral biomedical holdings (ENUM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of F...
Total Annual Compensation: $85.4K
Vice President of Business Development
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2014.

enumeral biomedical holdings (ENUM) Key Developments

Enumeral Biomedical Holdings, Inc. Announces Recent Progress in its PD-1 Antibody Program

Enumeral Biomedical Holdings, Inc. announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the company's R&D pipeline, including its TIM-3 antibody program. Enumeral has identified antibodies that appear to bind to PD-1 in a manner different from that of currently marketed anti-PD1 antibodies, while retaining activity in cell-based assays. The company has isolated more than 300 sequences of PD-1 binding antibodies from primary B cells in its PD-1 program. The company's bioinformatics analysis of sequences indicates that these antibodies are diverse, falling into 26 distinct clades, or families, that bind to PD-1. Enumeral has advanced six lead clones into pre-clinical characterization, four of which are undergoing humanization. The company anticipates that the humanization process will be completed by the end of the third quarter of 2015, which will enable initiation of cell line development for IND-enabling studies. In Enumeral's TIM-3 program, the company has isolated 180 screening hits and has sequenced 88 TIM-3 binding antibodies to date, and its screening efforts are ongoing. Enumeral's bioinformatics analysis indicates desirable diversity, with the antibodies falling into 17 unique clades that bind to TIM-3. Enumeral plans to apply its unique approach to cellular immune response profiling to further understand the utility of these different antibodies for modulation of different TILs. The company believes antibodies that block TIM-3 may potentiate anti-cancer immune responses, either as a monotherapy or in combination with other therapies, including other immune checkpoint-targeted drugs. The company currently anticipates nominating lead clones by the end of the third quarter 2015, and beginning the humanization process by the end of this year. Enumeral also noted that it is engaged in ongoing antibody screening in its LAG-3, OX40, and VISTA programs. Using human biopsy samples, the company intends to validate antibody blocking effects against these targets, and then assess potential monotherapy or combination therapy regimens using proprietary antibodies.

Enumeral Biomedical Holdings, Inc. Approves Amendment to the Certificate of Incorporation

Enumeral Biomedical Holdings, Inc. approved amendment to the certificate of incorporation at its AGM held on June 18, 2015.

Enumeral Biomedical Holdings, Inc. Announces Executive Appointments

Enumeral Biomedical Holdings, Inc. announced the expansion of its Scientific Advisory Board with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Dr. Draetta is Director of the Institute for Applied Cancer Science at M.D. Anderson Cancer Center, where he is also Professor of Genomic Medicine and Professor of Molecular and Cellular Oncology. His research focuses on identifying disease-driving genes associated with melanoma, glioblastoma and pancreatic cancer. Prior to joining M.D. Anderson, Dr. Draetta was the Chief Research Business Development Officer and Deputy Director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute. He previously served as Merck Research Laboratories’ Vice President and Worldwide Basic Franchise Head of Oncology. Dr. Draetta is a co-founder of Karyopharm, which develops inhibitors of nuclear transport targets for the treatment of cancer and other diseases. He also was the co-founder and Head of Research of Mitotix (acquired by GPC Biotech), where he established programs in cancer, inflammation and infectious diseases. Dr. Wucherpfennig, M.D., Ph.D., is Professor and Co-chair of the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His work focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment with in vivo models and using these insights for the development of cancer immunotherapies. Dr. Wucherpfennig election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENUM:US $0.50 USD -0.10

ENUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENUM.
View Industry Companies
 

Industry Analysis

ENUM

Industry Average

Valuation ENUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.8x
Price/Book 40.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 51.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENUMERAL BIOMEDICAL HOLDINGS, please visit www.enumeral.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.